OrbusNeich Medical Secures $200 Million in Funding Led by Shenzhen Capital Group to Accelerate Global Expansion and R&D

VCBeat (WeChat ID: vcbeat) has learned that OrbusNeich Medical Group Limited (“OrbusNeich”), a global leader in vascular interventional devices, recently announced it had secured approximately $200 million in financing.

This round of financing was led by Shenzhen Capital Group and its Hongtu Medical Fund, with participation from CCB International, Galaxy Capital, Wanhui Capital, China Merchants Securities Investment, and others.OrbusNeich stated that this round of financing will accelerate the continuous research and development of its new products and further expand the Group’s existing business across the Greater China region and globally.

This round of financing follows closely on the heels of OrbusNeich’s tens-of-millions-of-dollars Series A funding completed not long ago. The Series A round was co-led by CICC Qide Fund, under CICC Capital, and China Merchants Securities Investment, with Fenxiang Investment participating as a co-investor. The successful completion of these two consecutive financing rounds fully demonstrates the high recognition by professional investment institutions of OrbusNeich’s future development potential.

China Renaissance and CITIC Securities served as financial advisors to OrbusNeich in this round of financing.

Headquartered in Hong Kong, China, OrbusNeich is a globally oriented innovator in vascular interventional medical devices, with manufacturing and R&D bases in China, the Netherlands, and the United States, and branch offices spanning the globe. The company’s vascular interventional portfolio includes catheters for coronary and peripheral interventions, balloon dilation catheters, scoring balloons, and innovative drug-coated stents. Additionally, several blockbuster products are under development, such as neurointerventional balloons and heart valves from its joint ventures. Over the years, OrbusNeich’s products have been sold to dozens of countries worldwide, earning a strong reputation both domestically and internationally and receiving consistent acclaim from clinical experts around the world.

Mr. Qian Yongxun, CEO of OrbusNeich, stated“Since its inception, OrbusNeich has been dedicated to the research and development of innovative vascular interventional medical devices. With the strong support of our investor partners in this financing round, we will continue to intensify our innovation and R&D efforts to manufacture better and more comprehensive products. Backed by a professional and focused R&D team, world-class manufacturing processes, and a mature global sales network, OrbusNeich remains committed to delivering sustained benefits to cardiovascular disease patients worldwide.”

Zhou Yi, General Manager of the Shenzhen Capital Group Hongtu Medical Fund, stated“OrbusNeich is a globally positioned cardiovascular interventional device company. For many years, OrbusNeich has competed alongside international giants in overseas markets, a rarity among domestic manufacturers of high-value cardiovascular consumables. Shenzhen Capital Group and Hongtu Medical Fund firmly support OrbusNeich in achieving greater breakthroughs in its existing business and future innovative products.”

Liang Ying, Managing Director of CICC Capital and Head of the CICC Qide Fund, stated“OrbusNeich is a leading Chinese enterprise in vascular intervention with global competitiveness. Its management team possesses a global perspective and international operational capabilities, guiding the company to root itself in China while integrating with the world. After 20 years of dedicated refinement, the company’s products have earned an outstanding reputation within the industry, with sales spanning the globe and leading market shares in developed markets such as Japan and Europe. Meanwhile, the company has made substantial investments in R&D, mastering advanced technologies including globally leading pre-loaded dry valve systems, second-generation antibody coatings, and innovative drug-coated balloons. We believe that under the leadership of its excellent management team, the company will achieve rapid and high-quality development.”

Zhan Guifeng, General Manager of Investment at China Merchants Securities, stated“OrbusNeich’s product portfolio achieves comprehensive coverage of cardiovascular interventional therapies, with products already launched and sold in both coronary and peripheral interventions, while actively expanding into neurointervention and structural heart disease. The OrbusNeich team possesses a global perspective, diligently developing innovative products worldwide and continuously introducing international innovations to the Chinese market. We remain optimistic about the company’s sales expansion in the domestic market.”

Mr. Huang Fanzhi, Co-founder of Fenxiang Investment and Managing Partner of its Healthcare Fund, stated“Over the past several years, the vascular interventional device industry has experienced rapid growth, with import substitution accelerating significantly in recent years. Through years of technological accumulation, OrbusNeich has mastered multiple core technologies and has established layout and expansion plans in areas such as functional balloons, innovative drug-coated balloons, and neurointerventional consumables. The company’s portfolio of vascular interventional products is becoming increasingly comprehensive and diverse, with a solid market foundation and strong brand influence in developed markets including Europe, the United States, and Japan. The pre-loaded dry valve technology mastered by the company holds immense potential for future development. We are delighted to have the opportunity to collaborate with OrbusNeich to further promote the clinical application and advancement of innovative vascular interventional products.”

Li Gang, Partner and Co-Head of the Healthcare Industry at China Renaissance, stated“OrbusNeich is the first high-caliber domestic brand of vascular interventional devices to achieve a truly global footprint. We are honored to have facilitated the company’s latest round of financing, and we look forward to witnessing more milestone achievements as it continues its journey toward becoming a leading global player in the fields of vascular intervention and structural heart disease. We will continue to move forward hand in hand.”